Your browser is no longer supported. Please, upgrade your browser.
ADVM Adverum Biotechnologies, Inc. daily Stock Chart
ADVM [NASD]
Adverum Biotechnologies, Inc.
Index- P/E- EPS (ttm)-1.53 Insider Own3.20% Shs Outstand43.31M Perf Week-3.92%
Market Cap106.11M Forward P/E- EPS next Y-1.25 Insider Trans0.00% Shs Float38.74M Perf Month-7.55%
Income-64.20M PEG- EPS next Q-0.29 Inst Own53.00% Short Float1.24% Perf Quarter-10.09%
Sales1.80M P/S58.95 EPS this Y-68.50% Inst Trans-2.06% Short Ratio1.86 Perf Half Y-12.50%
Book/sh4.47 P/B0.55 EPS next Y3.80% ROA-27.90% Target Price3.50 Perf Year-43.94%
Cash/sh4.56 P/C0.54 EPS next 5Y- ROE-30.40% 52W Range2.45 - 4.55 Perf YTD-15.52%
Dividend- P/FCF- EPS past 5Y- ROI-53.10% 52W High-46.15% Beta-
Dividend %- Quick Ratio24.00 Sales past 5Y- Gross Margin- 52W Low0.00% ATR0.10
Employees61 Current Ratio24.00 Sales Q/Q66.70% Oper. Margin- RSI (14)32.34 Volatility2.85% 3.75%
OptionableYes Debt/Eq0.00 EPS Q/Q84.90% Profit Margin- Rel Volume0.61 Prev Close2.45
ShortableYes LT Debt/Eq0.00 EarningsAug 08 Payout- Avg Volume257.03K Price2.45
Recom2.50 SMA20-3.87% SMA50-6.45% SMA200-13.11% Volume156,186 Change0.00%
Aug-08-17 04:01PM  Adverum Biotechnologies Reports Second Quarter 2017 Financial Results and Provides Update GlobeNewswire
Aug-01-17 09:18AM  What's in the Cards for Adverum (ADVM) this Earnings Season? Zacks
Jun-20-17 09:00AM  Adverum Biotechnologies, Inc. Announces Appointment of Athena Countouriotis, M.D. as SVP and Chief Medical Officer GlobeNewswire
May-22-17 08:30AM  Adverum Biotechnologies to Present at the Jefferies Global Healthcare Conference GlobeNewswire
May-15-17 03:10PM  ETFs with exposure to Adverum Biotechnologies, Inc. : May 15, 2017 Capital Cube
May-12-17 11:57AM  Adverum Biotechnologies, Inc. :ADVM-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 Capital Cube +5.17%
May-10-17 05:30PM  Adverum Biotechnologies, Inc. Announces Data Presentations at the ARVO and ASGCT 2017 Annual Meetings GlobeNewswire
May-09-17 04:58PM  Adverum Biotechnologies posts 1Q loss Associated Press
04:00PM  Adverum Biotechnologies Reports First Quarter 2017 Financial Results and Provides Update GlobeNewswire
May-03-17 04:34PM  What's in Store for Adverum (ADVM) in Q1 Earnings? Zacks
Apr-20-17 09:00AM  Adverum Biotechnologies, Inc. Appoints Richard N. Spivey, Pharm.D., Ph.D. to Board of Directors GlobeNewswire
Apr-17-17 05:00PM  Adverum Biotechnologies Announces Updated Presentation Time for ARM 5th Annual Cell & Gene Therapy Investor Day GlobeNewswire
Apr-12-17 01:08PM  ETFs with exposure to Adverum Biotechnologies, Inc. : April 12, 2017 Capital Cube
Apr-06-17 08:30AM  Adverum Biotechnologies to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day GlobeNewswire
Mar-24-17 04:06PM  ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule
Mar-21-17 11:40AM  Adverum Biotechnologies, Inc. :ADVM-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Capital Cube -5.56%
Mar-20-17 04:11PM  ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Other Events
Mar-15-17 02:12PM  Adverum Biotechnologies, Inc. :ADVM-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Capital Cube
Mar-14-17 05:01PM  ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure
04:55PM  Adverum Biotechnologies, Inc. Appoints Patrick Machado, J.D. to Board of Directors GlobeNewswire
01:04PM  ADVERUM BIOTECHNOLOGIES, INC. Financials
Mar-09-17 06:06AM  ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 10-K, Annual Report
Mar-06-17 09:16AM  Adverum Biotechnologies posts 4Q loss Associated Press
09:08AM  ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
09:00AM  Adverum Biotechnologies Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Update GlobeNewswire
Mar-01-17 04:40PM  ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement +5.66%
Feb-27-17 06:23PM  Adverum (ADVM) to Post Q4 Earnings: What's in the Cards? Zacks
Feb-21-17 08:30AM  Adverum Biotechnologies to Present at Upcoming Investor Conferences GlobeNewswire
Feb-14-17 04:45PM  ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Feb-10-17 04:28PM  ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule +11.11%
Feb-03-17 04:08PM  ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Jan-18-17 05:41PM  Adverum Biotechnologies to Present At Phacilitate Cell & Gene Therapy World 2017 GlobeNewswire
Dec-19-16 09:44AM  Is KCAP Financial Inc (KCAP) A Good Stock to Buy? Insider Monkey
Dec-18-16 09:53PM  Is Osiris Therapeutics, Inc. (OSIR) A Good Stock To Buy? at Insider Monkey
Dec-14-16 06:16PM  Is Adverum Biotechnologies Inc (ADVM) a Good Stock to Buy? at Insider Monkey
Dec-09-16 04:51PM  ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement
Dec-05-16 11:45AM  ETFs with exposure to Adverum Biotechnologies, Inc. : December 5, 2016 +5.26%
Nov-28-16 10:57AM  Adverum Biotechnologies, Inc. :ADVM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016
Nov-16-16 03:28PM  Correction: Earns-Adverum Biotechnologies story
Nov-09-16 09:00AM  Adverum Biotechnologies to Present at Upcoming Investor Conferences GlobeNewswire +13.79%
Nov-08-16 04:15PM  ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:05PM  Adverum Biotechnologies, Inc. Reports Third Quarter 2016 Financial Results GlobeNewswire
08:10AM  Adverum (ADVM) Q3 Earnings Preview: What's in the Cards?
Nov-04-16 04:22PM  ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Oct-20-16 08:00AM  Adverum Biotechnologies Announces Data Presentations at the European Society of Gene and Cell Therapy (ESGCT) Meeting GlobeNewswire
Oct-14-16 07:18AM  ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure
07:01AM  Adverum Biotechnologies Provides Update on Alpha-1 Antitrypsin Deficiency Program GlobeNewswire
07:00AM  Adverum Biotechnologies, Inc. Announces New Executive Chair and CEO GlobeNewswire
Oct-13-16 04:13PM  ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
04:05PM  Adverum Biotechnologies to Present at the 2016 Ophthalmology Innovation Summit at the American Academy of Ophthalmology Annual Meeting GlobeNewswire
Sep-16-16 07:18AM  ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:05AM  Adverum Biotechnologies Presents Preclinical Data on Novel Gene Therapy Candidates for the Treatment of Wet AMD at The Retina Society 2016 Annual Meeting GlobeNewswire
Sep-14-16 09:46AM  ETFs with exposure to Adverum Biotechnologies, Inc. : September 14, 2016
Sep-02-16 04:09PM  ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule +5.35%
Sep-01-16 09:25AM  ETFs with exposure to Adverum Biotechnologies, Inc. : September 1, 2016
Aug-29-16 04:44PM  ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Aug-17-16 01:04PM  ETFs with exposure to Adverum Biotechnologies, Inc. : August 17, 2016 -5.11%
Aug-15-16 01:29PM  Adverum Biotechnologies, Inc. :ADVM-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016
Aug-11-16 09:31AM  Adverum (ADVM) Reports Narrower-than-Expected Q2 Loss
Aug-10-16 08:19AM  Jefferies Upgrades Editas Medicine To Buy, Positive On Partnerships & Progress On LCA 10 IND Testing
06:29AM  Avalanche Biotech reports 2Q loss
Aug-09-16 04:11PM  ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:05PM  Adverum Biotechnologies, Inc. Reports Second Quarter 2016 Financial Results GlobeNewswire
07:05AM  Adverum Biotechnologies and Editas Medicine Announce Collaboration to Explore Delivery of Genome Editing Medicines to the Eye GlobeNewswire
Aug-08-16 10:47AM  What's in Store for Adverum (ADVM) this Earnings Season?
Jul-19-16 11:53AM  ETFs with exposure to Adverum Biotechnologies, Inc. : July 19, 2016
Jul-07-16 04:26PM  ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:15PM  Adverum Biotechnologies Provides wet AMD Program Update GlobeNewswire
Jul-01-16 05:47PM  ETFs with exposure to Adverum Biotechnologies, Inc. : July 1, 2016 +5.38%
04:29PM  ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Jun-13-16 08:32AM  Adverum Biotechnologies Appoints Leone Patterson as Chief Financial Officer PR Newswire
07:16AM  ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure
Jun-08-16 06:47AM  Adverum Biotech downgraded by Chardan Capital Markets -7.74%
May-20-16 11:27AM  ETFs with exposure to Adverum Biotechnologies, Inc. : May 20, 2016
May-13-16 10:16AM  Adverum Biotechnologies, Inc. :ADVM-US: Earnings Analysis: Q1, 2016 By the Numbers -6.19%
May-12-16 07:10AM  ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisiti -6.28%
Adverum Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company is also developing AVA-201, a product candidate for the prevention of wet AMD; AVA-311 that is in preclinical studies for the treatment of juvenile X-linked retinoschisis, a rare genetic disease of the retina with no approved therapy; and AVA-322 and AVA-323 for the treatment of color vision deficiency. Avalanche Biotechnologies, Inc. has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.